ASCO 2026 Head & Neck AND Sarcoma Highlights – Drs. Samantha Armstrong & Ari Rosenberg

Welcome back to the Oncology Brothers podcast! In this episode, we dived into the key highlights from ASCO 2026, focusing on groundbreaking studies in head and neck cancer and sarcoma.Join us as we discuss:Nasopharyngeal Carcinoma: comparing carboplatin and cisplatin in induction and concurrent chemoradiation therapy. Can we extrapolate these findings to other head and neck cancers?Amivantamab in Head and Neck Cancer: Insights from the OrigAMI4 study, showcasing the efficacy of amivantamab in refractory settings, with an impressive overall response rate of 47%.SARC041: A look at abemaciclib as a treatment for de-differentiated liposarcoma, highlighting significant improvements in progression-free survival.Gastrointestinal Stromal Tumors (GIST): The PEAK trial results, explored the combination of bezuclastinib and sunitinib after progression on imatinib, showing promising outcomes.We are thrilled to have Dr. Ari Rosenberg from the University of Chicago and Dr. Sam Armstrong from Indiana University join us to share their expertise and insights on these important studies.Listen us on:Apple Podcast:https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966Follow us on social media:X/Twitter: https://twitter.com/oncbrothers⁠Instagram: https://www.instagram.com/oncbrothersWebsite: https://oncbrothers.com/Tune in for an informative discussion that sheds light on the latest advancements in oncology! Don’t forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers.#ASCO2026, #HeadAndNeckCancer, #Sarcoma, #GIST, #OncologyBrothers